Webinar: Hit discovery for trained immunity and tolerance

Do you want to learn about:

  • Trained immunity
  • The role of epigenetic targets in trained immunity
  • Hit discovery through ultra-high throughput screening of large libraries
  • Industry standard Hit-to-Lead biological profiling frameworks

Join Dr. Saman Honarnejad, Director Drug Discovery at Pivot Park Screening Centre​ on 14 December 3PM (GMT) for this webinar in which he will focus on epigenetic targets.

Dr Honarnejad will discuss:

  • The Center for Open Innovation in Lead Discovery (COILED) – a collaborative drug discovery program focused on epigenetic targets.
  • Modulation of trained innate immunity for treatment of hyper-inflammation and immune deficiency-driven diseases like sepsis and cancer.
  • The ultra-High Throughput Screening campaign of 300,000 diverse set of compounds has led to the identification of three novel scaffolds (starting points) that progressed into Hit-to-Lead phase.

​About the speaker

Dr. Saman Honarnejad is a biotechnologist with over a decade of experience in high-throughput biology. At Pivot Park Screening Centre (PPSC) in Oss, the Netherlands, he is involved in cellular and biochemical assay development, ultra-High Throughput screening (uHTS) and Hit-to-Lead biological compound profiling within a range of commercial, academic and public-private partnership projects including the European Lead Factory (ELF).

Prior to joining PPSC in 2017, he was active in high-content compound profiling method development at Max-Planck Institute (Germany), Harvard Medical School (United States) and Heidelberg University (Germany) and further optimised microarray-based cDNA/RNAi functional screening assays at the European Molecular Biology Laboratory (EMBL).

Date: 14 December 3PM (GMT)

Duration: 45 minutes

Register here



Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free